The newsletter

What actually moved in biotech, once a week.

Approvals, financings, and platform shifts across six beats, and what each one means for the decision in front of you. Written for founders, investors, and operators who need the read before the market has one.

Get the brief

Free. Takes about five minutes to read.

What to expect

One email a week

A single brief covering what moved across all six beats. No daily alerts and no drip sequence.

Pick your topics

After your email, you can choose which beats matter most to you. Skip it and you get everything.

Free, and easy to leave

No paywall and no cost. Every email has a one-click unsubscribe, and we do not sell your address.

Recently covered

Biotech Innovation

Proteomic Clocks Show Lower Biological Age Across Six Models In Rentosertib Phase 2a Trial, Extending Aging Endpoints Into IPF Drug Development

The study applied six proteomic clocks to serum proteomes from a published phase 2a trial of rentosertib, an AI-designed TNIK inhibitor being developed for idiopathic pulmonary fibrosis and aging-related biology. All six clocks moved in the same direction, but the paper also highlights a central limitation for the field: biomarker shifts still need contextual biological analysis before they can be read as clean anti-aging effects.

Healthcare Investment

ADARx Files For IPO To Fund Three Clinical siRNA Programs, Extending 2026 Biotech Listing Run

ADARx Pharmaceuticals is seeking fresh public-market capital despite entering 2026 with $427.3 million in cash, using the offering to support a wide clinical agenda across complement, hereditary angioedema and thrombosis-related programs. The move adds to this year's biotech IPO wave while showing that investors are again being asked to fund platform breadth, not just a single lead asset.

Healthcare Investment

MassBio And SCbio Select 10 Startups For Drive, Extending Early-Stage Support To Capital-Starved Founders

The latest Drive cohorts bring together companies working across small molecules, antibodies, gene editing, gene therapy, oncolytic viruses and cell therapy. For a market where the earliest financing remains hard to raise, the program is functioning less as publicity and more as infrastructure to help companies reach the next financing or development milestone.

Regulatory & Policy

Tactical Athletes Get New Cardiovascular Guidance, Expanding Care Standards Across 4 Million Workers

The new recommendations cover how clinicians should evaluate tactical athletes with cardiovascular disease or at risk of developing it in light of their professional demands. The guidance extends sports cardiology principles into service roles where sudden exertion, environmental extremes and stress can change the consequences of even common risk factors.

Biotech Innovation

Novartis Reports Pelacarsen Phase 3 Miss In 8,323 Patients, Leaving Lp(a) Field Open

Pelacarsen was being watched as the first phase 3 attempt to prove that lowering lipoprotein(a) changes cardiovascular outcomes, not just a biomarker. Novartis now says that link was not shown in the overall study population, shifting attention to whether deeper suppression or different trial designs from Amgen and Eli Lilly can produce a different result.